Q1 Earnings Estimate for AXSM Issued By HC Wainwright

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Thursday, February 20th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $0.11 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ FY2026 earnings at $7.52 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Other research analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 target price on the stock. Needham & Company LLC upped their target price on shares of Axsome Therapeutics from $133.00 to $153.00 and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research report on Wednesday. Bank of America upped their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Finally, Leerink Partners upped their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.64.

Axsome Therapeutics Trading Up 6.7 %

NASDAQ AXSM opened at $137.75 on Friday. The firm’s 50-day moving average is $101.29 and its two-hundred day moving average is $94.84. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.37. The stock has a market capitalization of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after buying an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in shares of Axsome Therapeutics in the fourth quarter valued at $2,599,000. PDT Partners LLC purchased a new position in shares of Axsome Therapeutics in the third quarter valued at $1,052,000. Pallas Capital Advisors LLC purchased a new position in shares of Axsome Therapeutics in the fourth quarter valued at $2,237,000. Finally, Captrust Financial Advisors purchased a new position in shares of Axsome Therapeutics in the third quarter valued at $514,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.